The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation…

HR+/HER2-negative Breast Cancer

~Estimated

~$10 – $7,500

Totus MedicinesNCT05683418

Phase 1

Study to Assess the Safety and Efficacy of Evexomostat (SDX-7320) in Combination With A PI3K or Akt Inhibitor Plus Fulvestrant in Patients With HR+, HER2-, Metastatic Breast Cancer With PI3K Pathway Alteration(s)

This is a Phase 1b/2, open-label, parallel-arms pilot study in men and post-menopausal women with hormone receptor positive (HR+), HER2- advanced or metastatic…

HR+/HER2-negative Breast CancerMetastatic Breast Cancer

~Estimated

~$10 – $8,750

SynDevRx, Inc.NCT05455619